Vitals Knowledge Vault

Alpha-Ketoglutarate

10 min read

Alpha-Ketoglutarate

TL;DR

Alpha-ketoglutarate (AKG) is an endogenous Krebs cycle intermediate with plausible multi-target anti-aging mechanisms (mTOR inhibition, autophagy induction, epigenetic modulation, collagen synthesis, mitochondrial anaplerosis). The scientific case is biologically serious. However, the only human longevity evidence is one open-label, industry-affiliated cohort study (Demidenko 2021) showing extraordinary 8-year DNAm age reduction — this result requires independent replication before it can be treated as credible.

The ABLE trial (double-blind placebo-controlled RCT of CaAKG 1g/day, n=120) is the gating data point. Until it reports, no AKG longevity claim can be treated as evidence-backed.

⚠️ Core tension: AKG is simultaneously marketed as an mTOR inhibitor (longevity) and a muscle-builder. These are contradictory — mTOR activation is required for muscle protein synthesis. The evidence does not support both claims simultaneously.

Why it Matters for Vitals

  • Epigenetic age tracking: If supplementing, track DNAm clocks (Horvath) to establish personal response — but do not over-interpret a single clock reading
  • Inflammation: ABLE trial primary endpoints are IL-6, TNF-α, CRP — relevant for Vitals users tracking systemic inflammation
  • Bone density: CTX reduction signal (37% in osteopenic women) is the most clinically concrete AKG benefit — relevant for older adults
  • mTOR contradiction coaching flag: Any Vitals user taking AKG for muscle-building should be informed the mTOR inhibition mechanism may be working against that goal
  • Age dependency: Rationale is strongest in middle/older adults where endogenous AKG declines; essentially absent for younger adults
  • Microbiome dependency: AKG benefit is attenuated in users with dysbiosis or recent antibiotic use
  • Formulation matters: Sustained-release CaAKG (used in all human studies) is more defensible than generic AKG powder

Key Facts

StatusGRAS (FDA); human data limited to one open-label industry cohort + one osteoporosis RCT; ABLE RCT pending
Primary mechanismKrebs cycle intermediate; AMPK activation → mTORC1 inhibition; TET demethylase co-factor; prolyl hydroxylase co-factor
Key human evidenceDemidenko 2021: ~8-year DNAm age reduction (n=42, open-label, industry-affiliated, requires replication); Filip RCT: 37% CTX reduction in osteopenic women
Gating data pointABLE trial: CaAKG 1g/day sustained-release × 6 months, double-blind placebo-controlled, n=120 — results expected 2024+
Dosing (research)CaAKG 1g/day sustained-release (Demidenko, ABLE); up to 6g/day CaAKG in osteoporosis RCTs
Key riskLong-term safety completely uncharacterized; theoretical cancer risk via mTOR/TET modulation; GI disturbance at high doses
Evidence levelPreliminary — hypothesis-generating, not proof

Claims Registry (BATCH44 Evidence Grades)

ClaimGradeNotes
AKG extends C. elegans lifespan ~50% (AMPK/HLH-30/autophagy-dependent)ConfirmedRobust, replicated across labs; PMID 25524759
CaAKG 1% w/w in mouse diet extends lifespan and improves healthspan; female > maleSupportedPMID 29700473; generalizability to humans is the open question
Demidenko 2021: ~8-year DNAm age reduction (n=42, open-label, industry-affiliated)ContestedExtraordinary claim requiring extraordinary replication; do not state as fact
AKG inhibits mTORC1 indirectly via AMPK activation in vitroContestedDose translation to oral supplement doses unestablished
AKG is direct cosubstrate for prolyl hydroxylase → collagen synthesisConfirmedDirect biochemical pathway
Oral AKG PK/bioavailability in humans not well-quantifiedGapMost important PK gap for the supplement
High-dose OKG (10g/day) acceptable safety profile short-termSupportedNot generalizable to typical longevity doses
DMK: superior cell penetration in vitro; no human comparative dataGapNo human bioavailability data
mTOR contradiction: marketed simultaneously as longevity (mTOR↓) and muscle-builder (MPS requires mTOR↑)Gap / CriticalCentral unresolved tension; do not present both claims
Industry affiliation: Demidenko study funded by Ponce de Leon Health (Rejuvant maker)ContestedKennedy BK on advisory board; disclose in any Vitals note
Endogenous AKG/Krebs cycle efficiency declines with ageSupportedSupports age-stratified supplementation rationale
No completed independent RCT has confirmed any AKG longevity benefit in humansGapABLE is the gating data point
Long-term (>12 month) safety in healthy adultsGapUnknown
Drug interactions for AKGGapCompletely uncharacterized

The mTOR Contradiction

This is the most important unresolved tension in the AKG longevity literature.

AKG is simultaneously marketed as:

  • An mTOR inhibitor for longevity (anti-aging) — mTOR inhibition activates autophagy and is associated with extended lifespan in model organisms
  • A muscle-building supplement — mTOR activation is required for muscle protein synthesis (MPS)

These are biochemically contradictory claims. mTOR inhibition suppresses MPS. Anaplerotic muscle benefit is theoretically possible but has not been demonstrated in humans at longevity doses.

Coaching implication: If a Vitals user’s primary goal is longevity (mTOR down), AKG is theoretically coherent. If the primary goal is muscle rebuilding, AKG’s mTOR effect is counterproductive. These are distinct goals requiring different interventions.

See also: mTOR AMPK Muscle Catabolism

Mechanism Summary

Krebs Cycle / Anaplerosis

AKG is a key intermediate in the Krebs cycle. Flux generates ATP and provides carbon skeletons for anabolism. Supplemental AKG is hypothesized to support mitochondrial efficiency by replenishing Krebs cycle intermediates that decline with age. Biochemical role established; translation to supplementation benefit not.

mTOR Inhibition

AKG inhibits mTORC1 indirectly via AMPK activation and increased AMP:ATP ratio. This activates autophagy and reduces protein synthesis. Mechanistically coherent in vitro; oral doses required for tissue mTOR inhibition in humans are unestablished.

Collagen Synthesis

AKG is a direct cosubstrate for prolyl hydroxylase enzymes, which hydroxylate proline residues in collagen. This establishes a direct biochemical role for AKG in collagen synthesis. Mechanism is biochemically sound; human trial data for skin/beauty outcomes is thin and doses unclear. See Collagen Synthesis.

Epigenetic Modulation (TET / JmjC)

AKG is the obligate co-factor for TET DNA demethylases and JmjC histone demethylases. Age-related AKG depletion may impair these enzymes, leading to accumulation of repressive epigenetic marks. Mechanistically coherent; human evidence is limited to one industry cohort.

HIF-1α Normalization

Prolyl hydroxylases (PHDs) require O₂ + Fe(II) + AKG simultaneously. Age-related AKG depletion impairs PHDs even with O₂ present → HIF-1α aberrantly stabilized → pseudohypoxia and inflammation. AKG resupplementation may normalize this. Mechanistically supported; human data lacking.

Gut Microbiome

~95% of ingested AKG is bacterially metabolized. The microbiome-dependency of systemic effects means AKG benefit is attenuated in users with dysbiosis or recent antibiotic use.

Human Evidence

Demidenko 2021 — The Only Human Longevity Study

Open-label cohort (n=42), 8-year follow-up, sustained-release CaAKG 1g/day. Reported ~8-year apparent reduction in Horvath DNAm clock.

Critical limitations:

  • Open-label, self-selected participants (no placebo control)
  • No pre-registered analysis plan
  • Industry-affiliated (Ponce de Leon Health, maker of Rejuvant)
  • Statistical significance (p=6.5e-12) is extraordinary and requires extraordinary replication
  • Sample size (n=42) is very small for such a large effect estimate

Verdict: Hypothesis-generating signal. Not proof. Requires independent replication.

Always disclose industry affiliation when referencing this study.

The ABLE Trial — The Gating Data Point

Double-blind placebo-controlled RCT of CaAKG 1g/day sustained-release × 6 months, n=120. Primary endpoints: inflammatory markers (IL-6, TNF-α, CRP) and physical function.

Significance: This is the only properly designed independent RCT for AKG. Until ABLE reports, no AKG longevity claim can be treated as evidence-backed.

Characterization rule: Always describe as PENDING. Never characterize as positive or negative.

Filip Osteoporosis RCT

n=76 postmenopausal women with osteopenia, 6 months, CaAKG 6g/day. CTX (bone resorption marker) ↓ 37%. This is the most clinically concrete AKG benefit with the best-designed study for a specific outcome.

Formulation Comparison

FormNotesQuality Score
Sustained-release CaAKGUsed in Demidenko and ABLE trial; better stability9/10
Immediate-release CaAKGInferior plasma exposure vs. sustained-release6/10
Free acid AKGAqueous dilution improves absorption; commercial capsules may have inferior absorption5/10
Generic AKG powderNo FDA quality standards; batch-to-batch variability3/10
DMKLipophilic ester; superior cell penetration in vitro; no human data4/10

No FDA quality standards apply to AKG supplements.

Comparison with Other Longevity Compounds

vs. Rapamycin

Rapamycin has the strongest and most reproducible mouse lifespan data of any pharmacological intervention. Direct and potent mTORC1 inhibition. AKG’s mTOR effect is indirect and much weaker. Rapamycin has human safety data from transplant/oncology use. Verdict: Rapamycin > AKG on current evidence quality.

vs. Metformin

Metformin has the most human longevity evidence of any AMPK-activating compound (TAME pending, MILES completed, Bannister observational). AKG has one open-label industry cohort study. Verdict: Metformin > AKG on current evidence quality.

vs. NAD+ Precursors (NMN, NR)

NAD+ precursors have multiple human trials showing increased NAD+ levels and some metabolic benefits. More human trial data than AKG. Neither has completed large RCTs for longevity outcomes. Verdict: NAD+ precursors ≥ AKG on current evidence quality.

Biomarkers to Track (If Supplementing)

BiomarkerFrequencyRationale
IL-6, TNF-α, CRP (inflammation)Baseline + 6 monthsABLE trial primary endpoints
Fasting insulin + HOMA-IRBaseline + 6 monthsMetabolic health proxy
Grip strengthBaseline + 6 monthsFunctional proxy
BUN/ureaBaseline + 6 monthsNitrogen balance proxy
Epigenetic age (DNAm clock)Baseline + 12 monthsOnly if personal tracking; do not over-interpret single readings

Safety

What We Know

  • Short-term (up to 6 months, ABLE trial): not alarming
  • High-dose OKG (10g/day): acceptable safety profile short-term
  • GRAS status (FDA)

What We Don’t Know

  • Long-term (>12 months) safety in healthy adults — completely uncharacterized
  • Drug interactions — completely uncharacterized
  • Effect in populations with kidney disease
  • Theoretical cancer risk via mTOR/TET modulation — no human data

Vitals Implementation Rules

The following rules apply before any AKG recommendation enters the Vitals system:

Do NOT recommend AKG for longevity purposes without disclosing:

  1. The only human longevity evidence is one open-label, industry-affiliated cohort study
  2. ABLE trial results are the gating data point
  3. The mTOR contradiction if user is also seeking muscle-building goals

Requires human signoff before vault entry:

  • Any AKG supplement recommendation for longevity
  • AKG + rapamycin or AKG + metformin stack recommendations (no combination data)
  • Claims about measurable biological age reversal from AKG
  • AKG for skin/collagen claims (human data thin)
  • Using AKG specifically for mitochondrial efficiency (no validated biomarker)

Age-stratified rationale:

  • Age <40: supplementation rationale essentially absent (no deficiency state)
  • Age 40–65: most theoretically justified; endogenous decline is documented
  • Age 65+: strongest rationale; most consistent with aging biology

Algorithm Hooks

AKG Evidence Assessment Protocol

def akg_evidence_assessment(patient_age: int, primary_goal: str) -> dict:
    if patient_age < 40:
        return {
            "recommendation": "NOT_RECOMMENDED",
            "rationale": "Endogenous AKG decline is age-related; young adults have no deficiency state",
            "evidence_level": "essentially_absent_for_young_adults",
        }
    if primary_goal == "muscle_building":
        return {
            "recommendation": "NOT_RECOMMENDED_FOR_THIS_GOAL",
            "rationale": "AKG marketed as mTOR inhibitor for longevity; mTOR ACTIVATION required for MPS; these are contradictory",
            "human_signoff_required": True,
            "caveat": "Evidence does not support muscle-building claim at longevity doses",
        }
    if primary_goal == "longevity":
        return {
            "recommendation": "WAIT_FOR_ABLE_TRIAL",
            "rationale": "Only one industry-affiliated human study exists; ABLE RCT is gating data point",
            "evidence_level": "preliminary_hypothesis_generating",
            "able_trial_status": "PENDING",
            "human_signoff_required": True,
            "caveat": "Do not characterize Demidenko 2021 as proof — open-label, industry-affiliated, requires replication",
        }
    return {
        "recommendation": "INSUFFICIENT_EVIDENCE",
        "rationale": "No completed independent RCT confirms any AKG longevity benefit",
    }

ABLE Trial Status

def able_trial_status() -> dict:
    return {
        "trial": "CaAKG 1g/day sustained-release × 6 months, double-blind placebo-controlled, n=120",
        "primary_endpoints": ["inflammatory markers (IL-6, TNF-α, CRP)", "physical function (grip strength, etc.)"],
        "formulation": "sustained-release CaAKG (not generic AKG powder)",
        "status": "RESULTS_EXPECTED_2024_PLUS",
        "as_of": "2026-04-20",
        "significance": "ONLY properly designed independent RCT for AKG; gating data point",
        "if_positive": "First independent RCT confirmation of AKG biological activity in humans",
        "if_null_or_negative": "Only human longevity evidence collapses to single industry cohort",
        "characterization_rule": "ALWAYS describe as PENDING; never as positive or negative",
    }

AKG Formulation Quality Guide

def akg_formulation_quality(product_form: str, sustained_release: bool) -> dict:
    if not sustained_release:
        return {
            "assessment": "INFERIOR_TO_RESEARCH_FORM",
            "rationale": "ABLE trial uses sustained-release CaAKG; immediate-release has sharp plasma peaks",
        }
    quality_score = {
        "sustained_release_CaAKG": 9,  # used in Demidenko and ABLE
        "immediate_release_CaAKG": 6,
        "free_acid_AKG": 5,
        "generic_AKG_powder": 3,
        "DMK": 4,  # better cell penetration in vitro; no human data
    }
    return {
        "form": product_form,
        "assessment_score": quality_score.get(product_form, 3),
        "note": "No FDA quality standards apply to AKG supplements; batch-to-batch variability is a real concern",
    }

Graph View

Backlinks